Rx Item-Emgality 100MG/ML 3 PFS-KEEP REFRIG- by Lilly Eli & Co USA

Rx Item-Emgality 100MG/ML GALCANEZUMAB 3 PFS-Keep Refrigerated - by Lilly Eli & Co USA

Rx Item-Emgality 100MG/ML 3 PFS-Keep Refrigerated - by Lilly Eli & Co USA, Item No. RX880054, 880054, NDC No.: 00002-3115-09, 00002-115-09, 0000211509, 00002311509, 3115-09, 311509 UPC No. 3-00023-11509-6, 300023-115096, 300023115096, Category:RX, Brand Drug Classification: Antimigraine Agents Drug Class: Drug Class: 28321200 Calcitonin Gene- Related Peptide Antag. Brand/generic: Other Names: Galcanezumab-Gnlm Subcut, Emgality, Emgality, Galcanezumab-Gnlm Subcut, Emgality

Part Number: RX880054

Feature: Drug Class: Drug Class: 28321200 Calcitonin Gene- Related Peptide Antag.

Feature: OMP Family: Waiting for Details

Feature: Temparature Zone: 30 Refrige./DoNot Freez

Feature: Unit Dose Indicator: NO

Feature 5 Item Size: 3

You need to be a registered customer to order this product. Please Login to your account or click here to Register.

The item you are trying to purchase is currently out of stock.
Please enter your name, email, and phone number below.
We will contact you as soon as this product is available.

Name: *

Email: *

Phone: *

Verification: *

Type the word above...

Description
Feature 6
Feature 7
Feature 8
Feature 9
Feature 10
Feature 11
Feature 12
Feature 13

Clinical Information

Gen. Code and Des.

79818 galcanezumab-gnlm SUBCUT SYRINGE 300MG/3ML

GCN and Des.

46397 galcanezumab-gnlm SUBCUT SYRINGE 300MG/3ML

Strength

100MG/ML

Dose Form

SYRINGE (ML)

Product Category

RX Pharmaceuticals

Fine Line Class

850085008510 All Rx Products

DEA Class

OMP Family

AHFS Class

28321200 CALCITONIN GENE-RELATED PEPTIDE ANTAG.

Active Ingredients

17757 galcanezumab-gnlm

Inactive Ingredients

2551 polysorbates 9005645

these highlights do not include all the information needed to use EMGALITY safely and effectively. See full prescribing information for EMGALITY.

EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use

Initial U.S. Approval: 2018

INDICATIONS AND USAGE

EMGALITY? is a calcitonin-gene related peptide antagonist indicated for the preventive treatment of migraine in adults. (1)

DOSAGE AND ADMINISTRATION

For subcutaneous use only. (2.1, 2.2)

Recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg. (2.1)

Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. (2.2)

DOSAGE FORMS AND STRENGTHS

Injection: 120 mg/mL solution in a single-dose prefilled pen (3)

Injection: 120 mg/mL solution in a single-dose prefilled syringe (3)

CONTRAINDICATIONS

EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. (4)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy. Hypersensitivity reactions could occur days after administration, and may be prolonged. (5.1)

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 9/2018

Rx Item-Emgality 100MG/ML GALCANEZUMAB 3 PFS-Keep Refrigerated - by Lilly Eli & Co USA

Recently Viewed Items